Using of systemic enzymotherapy for treatment of rheumatoid arthritis

Kovalenko V.,Golovkov Y., Golovatcky I. 

Ukrainian Centre of Rheumatology, Kiev, Ukraine

2^nd Central European Congress of Rheumatology, 13 – 16 May, 1998, Warsaw, Poland
published in Rheumatologia 1998, Suppl., Vol. XXXVI, Warsaw 1998, Abst. No. 140, pp. 206 
ISSN 0034-6233

619 KA (19-09-2)

We applied the drug WOBENZYM (MUCOS Pharma Gmbh & Co., Germany) in the complex treatment of 25 rheumatoid arthritis (RA) patients (mean age 62,1+4,4 years), which formed the basic group (BG), parallel with NSAIDs. In 27 patients of the control group (CG) there were used only NSAIDs. The both groups were comparable by the age, severity of their disease, and accompanying diseases.
The WOBENZYM was given during 30 days, at the dose of 10 tablets 3 times a day. The treatment efficacy was estimated by the data of clinical, laboratory and instrumental findings.
The intensity of pain syndrome (by 10-scale) reduced in pts of BG from 6,85±0,28 to 2,80+0,19 units /u./ (p<0,01), while in pts of CG from 7,04±0,26 to 3,87±0,24 (p<0,01), but this reduction was more pronounced in pts of BG (p<0,01).
Pain reduction by 50% was observed in 85% of BG but only in 39,1% of CG pts (p<0,05). Patient self-evaluation of treatment efficacy coincided with physician evaluation in 87,5% of BG pts, while in CG -68% (p<0,05). There was observed positive dynamics of Stanford form indices: from 31,2±3,5 to 22,1±3,4 in the BG (p<0,05), while in the CG changes were insignificant. Also we have observed increase of hand strength in BG and CG by 4,52±0,86 kg and 2,27±0,51 kg, accordingly (p<0,05). We have not observed adverse reactions in BG, while in 20% of CG pts (p<0,01). By infrared thermography data resumption of inflammatory process, or its essential reduction was stated, ESR also decreased (p<0,05).
Thus WOBENZYM application in complex treatment of RA pts permits to get effective curative results at absence of indesirable effects.